Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

US Pharmaceuticals Ishares ETF (IHE)

US Pharmaceuticals Ishares ETF (IHE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family BlackRock iShares
  • Assets Under Management 668,633,000
  • Shares Outstanding, K 8,050
  • 60-Month Beta 0.54
  • Price/Earnings ttm 24.26
  • Annual Dividend & Yield 1.12 (1.35%)
  • Most Recent Dividend 0.312 on 09/16/25
  • Management Fee 0.39%
  • INDUSTRY GROUPING:

    ETFs - Biotech

Options Overview Details

View History
  • Implied Volatility 26.01% (+0.04%)
  • Historical Volatility 16.90%
  • IV Percentile 80%
  • IV Rank 45.13%
  • IV High 49.42% on 04/09/25
  • IV Low 6.76% on 09/03/25
  • Expected Move (DTE 14) 2.98 (3.58%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 14
  • Put/Call OI Ratio 2.28
  • Today's Open Interest 387
  • Open Int (30-Day) 370
  • Expected Range 80.09 to 86.04

Price Performance

See More
Period Period Low Period High Performance
1-Month
75.03 +10.70%
on 11/07/25
86.17 -3.61%
on 11/26/25
+7.08 (+9.32%)
since 11/04/25
3-Month
69.02 +20.34%
on 09/25/25
86.17 -3.61%
on 11/26/25
+11.82 (+16.59%)
since 09/04/25
52-Week
58.97 +40.84%
on 04/09/25
86.17 -3.61%
on 11/26/25
+14.01 (+20.29%)
since 12/04/24

Most Recent Stories

More News
Viatris Stock: Is Wall Street Bullish or Bearish?

Viatris has underperformed the broader market in recent months, and analysts’ outlook remains guarded as the company executes on its transformation efforts.

TFC : 47.54 (+0.25%)
$SPX : 6,857.12 (+0.11%)
VTRS : 10.76 (-0.74%)
IHE : 83.06 (-0.88%)
Are Wall Street Analysts Predicting Bristol-Myers Squibb Stock Will Climb or Sink?

Bristol-Myers Squibb has significantly underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

$SPX : 6,857.12 (+0.11%)
IHE : 83.06 (-0.88%)
PIPR : 338.67 (+1.99%)
BMY : 51.95 (+1.94%)
How Is Bristol-Myers’ Stock Performance Compared to Other Pharma Stocks?

Bristol-Myers Squibb has notably underperformed the broader pharma space over the past year, and analysts have turned cautious on the stock’s prospects.

IHE : 83.06 (-0.88%)
REGN : 722.80 (-0.12%)
BMY : 51.95 (+1.94%)
How Is Regeneron’s Stock Performance Compared to Other Pharma Stocks?

Regeneron Pharmaceuticals has significantly underperformed the broader pharma space over the past year, yet analysts remain optimistic about the stock’s prospects.

BGNE : 184.71 (+0.49%)
IHE : 83.06 (-0.88%)
REGN : 722.80 (-0.12%)
ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data

Eli Lilly and Company LLY reported robust second-quarter 2025 results, wherein it beat estimates on both the top and bottom lines, driven by strong demand for its blockbuster weight loss and diabetes drugs....

NVO : 47.99 (+0.88%)
OZEM : 32.50 (+0.83%)
IHE : 83.06 (-0.88%)
LLY : 1,014.49 (-1.85%)
MEDX : 33.71 (-0.49%)
PPH : 99.85 (-0.69%)
MEDI : 31.87 (+0.20%)
Viatris Stock: Analyst Estimates & Ratings

Viatris has considerably underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

$SPX : 6,857.12 (+0.11%)
VTRS : 10.76 (-0.74%)
IHE : 83.06 (-0.88%)
GS : 837.83 (+0.15%)
Is Wall Street Bullish or Bearish on Merck Stock?

Despite Merck’s underperformance relative to the broader market over the past year, analysts continue to maintain fair confidence regarding its future potential.

WFC : 90.21 (+0.96%)
$SPX : 6,857.12 (+0.11%)
MRK : 100.89 (-1.35%)
IHE : 83.06 (-0.88%)
ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook

Johnson & Johnson JNJ reported stronger-than-expected second-quarter 2025 results. The world's biggest healthcare products maker continued with its long streak of earnings beat and also exceeded revenue...

XLV : 153.90 (-0.76%)
JNJ : 202.48 (-1.39%)
IHE : 83.06 (-0.88%)
IYH : 65.10 (-0.75%)
PPH : 99.85 (-0.69%)
FTXH : 32.59 (-0.49%)
Do Wall Street Analysts Like Viatris Stock?

Viatris has underperformed the broader market over the past year, and analysts remain skeptical of the stock’s future potential.

$SPX : 6,857.12 (+0.11%)
VTRS : 10.76 (-0.74%)
IHE : 83.06 (-0.88%)
JEF : 58.82 (+0.70%)
Are Wall Street Analysts Bullish on Merck Stock?

While Merck has trailed the broader market over the past year, analysts still see a reasonably promising path ahead for the pharma heavyweight.

$SPX : 6,857.12 (+0.11%)
MRK : 100.89 (-1.35%)
IHE : 83.06 (-0.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Fund Summary

The iShares U.S. Pharmaceuticals ETF seeks to track the investment results of an index composed of U.S. equities in the pharmaceuticals sector. The Fund seeks investment results that correspond to the price and yield of the Dow Jones U.S. Select Pharmaceuticals Index.

See More

Key Turning Points

3rd Resistance Point 84.34
2nd Resistance Point 84.01
1st Resistance Point 83.53
Last Price 83.06
1st Support Level 82.72
2nd Support Level 82.39
3rd Support Level 81.91

See More

52-Week High 86.17
Last Price 83.06
Fibonacci 61.8% 75.78
Fibonacci 50% 72.57
Fibonacci 38.2% 69.36
52-Week Low 58.97

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar